B.Riley Downgrades Gain Therapeutics (GANX) to Neutral

August 19, 2022 3:26 AM EDT
Get Alerts GANX Hot Sheet
Price: $3.26 +2.84%

Rating Summary:
    3 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 10 | Down: 4 | New: 31
Join SI Premium – FREE

B.Riley analyst Mayank Mamtani downgraded Gain Therapeutics (NASDAQ: GANX) from Buy to Neutral with a price target of $5.00 (from $11.00).

For an analyst ratings summary and ratings history on Gain Therapeutics click here. For more ratings news on Gain Therapeutics click here.

Shares of Gain Therapeutics closed at $3.82 yesterday.

You May Also Be Interested In

Related Categories

Analyst PT Change, Downgrades